Valeritas (NSDQ:VLRX) announced that the company and its subsidiaries filed voluntary petitions for Chapter 11 bankruptcy, having agreed to sell substantially all of the business to Zealand Pharma (CPH:ZEAL). The agreement is slated to provide a total cash consideration of $23 million along with certain liabilities related to the ongoing business. Once the acquisition is completed, Zealand […]
Valeritas
7 medtech advances to improve diabetes treatment
Medtech and pharmaceutical companies have made several important strides over the past year when it comes to improving diabetes treatment. Multiple treatments and technologies have cleared regulatory hurdles and are now hitting the market and making the process of living with diabetes that much more manageable. Several different styles of therapy and devices have come […]
Valeritas jumps on $25m refi, Q3 prelims
Valeritas (NSDQ:VLRX) said today that cut its debt load by $25 million in a refinancing move and released its third-quarter preliminary results, sending its share price up on Wall Street in early trading. The terms of refi saw the exchange of $25.0 million in senior debt owned by CR Group and another creditor for new Series […]
Valeritas touts h-Patch CBD study
Valeritas (NSDQ:VLRX) today announced positive results from its preclinical pharmacokinetic study of cannabidiol subcutaneous infusion. The study focused on delivering cannabidiol (CBD) through subcutaneous infusion through the company’s h-Patch Wearable Device. The results were presented at the CannMed Conference in Pasadena, Calif. Results from the study showed rapid and robust absorption and distribution of 40mg of […]
Valeritas touts study results
Valeritas (NSDQ:VLRX) today announced the results of a study that showed patients using its V-Go wearable insulin delivery device needed less insulin, had lower A1c levels and reduced diabetes-related medication cost compared with patients using multiple daily injection (MDI) therapy. The retrospective study by the Bridgewater, N.J.-based company used information from the HealthCore Integrated Research Database (HIRD). […]
ADA 2019: Hybrid closed-loop devices take center stage
The American Diabetes Association’s 79th Scientific Sessions is a five-day conference where researchers and healthcare professionals share the latest in diabetes research. More than 180 sessions and over 2,000 research presentations took place during the meeting on June 7-11 in San Francisco. During the meeting, diabetes experts shared data and research from clinical trials. Here are four […]
Valeritas touts ADA’s inclusion of patch-like insulin delivery devices in diabetes management guidelines
Valeritas (NSDQ:VLRX) said today that the American Diabetes Association has endorsed the use of “disposable patch-like devices” for insulin delivery, which includes its V-Go wearable insulin delivery device. The Bridgewater, N.J.-based company said that the endorsement was made as part of the the ADA’s annual Standards of Medical Care for 2019, published in the journal Diabetes […]
Valeritas board approves 1-for-20 reverse split
Valeritas (NSDQ:VLRX) said today that its board of directors approved a 1-for-20 reverse split of its common stock. Through the move, the Bridgewater, N.J.-based company said that each owner of its common stock will receive a single share for every 20 shares they previously held. Fractional shares as a result of the split will be settled […]
Valeritas shares fall despite Street-topping Q1 sales
Shares in Valeritas (NSDQ:VLRX) are down more than 15% in after-hours trading despite the medtech firm releasing first quarter 2019 earnings that beat sales expectations and met loss-per-share consensus from Wall Street analysts. The Bridgewater, N.J.-based company posted losses of approximately $14.7 million, or 15¢ per share, on sales of $6.4 million for the three months […]
Valeritas touts reduced A1c, insulin use in V-Go insulin delivery study
Valeritas (NSDQ:VLRX) today released results from the VERDICT study of its V-Go wearable insulin delivery device, touting improved A1c levels with less insulin. Data in the study came from a retrospective analysis of 139 patients with type 2 diabetes using the V-Go device, the Bridgewater, N.J.-based company said. Read the whole story on our sister site, […]
Valeritas inks Israeli distro deal with Tritech Biomed
Valeritas (NSDQ:VLRX) said today that it inked an exclusive distribution deal with Tritech Biomed to commercialize its V-Go wearable insulin delivery device designed for patients with Type 2 diabetes in Israel. Through the deal, the Bridgewater, N.J.-based company said that Tritech Biomed will have rights to promote, market and sell the V-Go system to diabetes clinics […]
